RxDoctor Payments Data

Jack Askins, MD

Interventional Cardiology · Wichita Falls, TXNPI 1316039712

Payments from drug & device makers

$1,869in general payments, 2019–2025

Across 39 payments — averaging $47.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$369
  • Bard Peripheral Vascular, Inc.$198
  • Beckman Coulter, Inc.$186
  • Inari Medical, Inc.$161
  • Merck$154
  • E.r. Squibb & Sons, L.L.C.$141
  • plus $660 from 11 others

What the payments were for

  • Food & beverage$1,83898%
  • Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,869 in reported general payments places this provider in the 10th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$221,054
Medicare patients
1,185
Services billed
3,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$167,276
XareltoRivaroxaban36$41,155
EntrestoSacubitril/Valsartan16$14,315
FarxigaDapagliflozin Propanediol12$6,728
Praluent PenAlirocumab11$5,114
Metoprolol Succinate330$4,560
ClopidogrelClopidogrel Bisulfate159$2,405
Rosuvastatin Calcium201$2,182
Losartan Potassium177$1,896
Digoxin73$1,789
Atorvastatin Calcium184$1,511
Amiodarone Hcl76$1,417
Nitroglycerin PatchNitroglycerin28$1,143
Metoprolol Tartrate123$1,074
Carvedilol143$1,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$167,276199 claims
Johnson & JohnsonXarelto$15$41,15536 claims
AstraZenecaFarxiga$114$6,72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →